Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line

Acta Pharmaceutica

Volumn 63, Issue 4, 2013, Pages 493-503

  Feridooni, Tiam ^a   Mac Donald, Chris ^b   Shao, Di ^a   Yeung, Pollen ^b   Agu, Remigius U ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cytoprotection; Dexrazoxane; Diltiazem; Doxorubicin; Irinotecan; Rat myoblast (H9c2)

Indexed keywords

CLADRIBINE; DILTIAZEM; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; LOSARTAN; RAZOXANE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CELL DEATH; CELL PROTECTION; CHEMOTHERAPY INDUCED CARDIOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; IC 50; IN VITRO STUDY; INCUBATION TIME; MYOBLAST; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARDIOVASCULAR AGENTS; CELL DEATH; CELL LINE; CELL SURVIVAL; DEXRAZOXANE; DILTIAZEM; DOXORUBICIN; HUMANS; INHIBITORY CONCENTRATION 50; LOSARTAN; MYOBLASTS; RATS;

EID: 84896124032     PISSN: 13300075     EISSN: 18469558     Source Type: Journal    
DOI: 10.2478/acph-2013-0038     Document Type: Article

References (29)

1. W. A. Denny, Emerging DNA topisomerase inhibitors as anticancer drugs, Expert Opin. Emerg. Drugs 9 (2004) 105-133; DOI: 10.1517/eoed.9.1.105.32948.
2. L. F. Liu, DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem. 58 (1989) 351-375; DOI: 10.1146/annurev.bi.58.070189.002031.
3. G. Takemura and H. Fujiwara, Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management, Prog. Cardiovasc. Dis. 49 (2007) 330-352; DOI: 10.1016/j.pcad.2006. 10.002.
4. S. Hitchcock-Bryan, R. Gelber, J. R. Cassady and S. E. Sallan, The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia, Med. Pediatr. Oncol. 14 (1986) 211-215; DOI: http://dx.doi.org/10.1002/mpo.2950140405.
5. T. Feridooni, A. Hotchkiss, S. Remley-Carr, Y. Saga and K. B. S. Pasumarthi, Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes, PLoS ONE 6 (2011) e22801; DOI: 10.1371/journal.pone.0022801.
6. X. Z. Han, S. Gao, Y. N. Cheng, Y. Z. Sun, W. Liu, L. L. Tang and D. M. Ren, Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes, Biosci. Trends 6 (2012) 19-25; DOI: 10.5582/bst.2012.v6.1.19.
7. B. Glimelius, Benefit-risk assessment of irinotecan in advanced colorectal cancer, Drug Saf. 28 (2005) 417-433; DOI: http://dx.doi.org/10.2165/ 00002018-200528050-00005.
8. J. Weekes, A. K.-Y. Lam, S. Sebesan and Y.-H. Ho, Irinotecan therapy and molecular targets in colorectal cancer: a systemic review, World J. Gastroenterol. 15 (2009) 3597-3602; DOI: http://dx. doi.org/10.3748/wjg.15.3597.
9. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev. 56 (2004) 185-229; DOI: 10.1124/pr.56.2.6.
10. R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair and T. D. Oberley, Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?, Antioxid. Redox Signal. 9 (2007) 1001-1008; DOI: 10.1089/ars.2007.1632.
11. E. H. Herman and V. J. Ferrans, Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds, Cancer Treat Rev. 14 (1987) 225-259; DOI: 10.1016/0305-7372(87) 90011-9.
12. S. M. Swain, F. S. Whaley, M. C. Gerber, M. S. Ewer, J. R. Bianchine and R. A. Gams, Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy, J. Clin. Oncol. 15 (1997) 1333-1340.
13. S. M. Swain and P. Vici, The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review, J. Cancer Res. Clin. Oncol. 130 (2004) 1-7; DOI: 10. 1007/s00432-003-0498-7.
14. M. S. Wolin, Interactions of oxidants with vascular signaling systems, Arterioscl. Throm. Vas. Biol. 20 (2000) 1430-1442; DOI: 10.1161/01.ATV.20.6. 1430.
15. D. B. Sawyer, R. Fukazawa, M. A. Arstall and R. A. Kelly, Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane, Circ. Res. 84 (1999) 257-65; DOI: 10.1161/01. RES.84.3.257.
16. J. Bierau, R. Leen, A. H. van Gennip, H. N. Caron and A. B. P. van Kuilenburg, Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine, J. Chromatogr. B 805 (2004) 339-346; DOI: 10.1016/j.jchromb.2004.03. 036.
17. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher and R. K. Jain, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, Proc. Natl. Acad. Sci. USA 108 (2011) 2909-2914; DOI: 10.1073/pnas.1018892108.
18. C. E. Runyan, H. W. Schnaper and A.-C. Poncelet, The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells, J. Biol. Chem. 280 (2005) 8300-8308; DOI: 10.1074/jbc.M407939200.
19. K. Tamaki, S. Okuda, T. Ando, T. Iwamoto, M. Nakayama and M. Fujishima, TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy, Kidney Int. 45 (1994) 525-536.
20. W. Zong, X. Yang, X. Chen, H. Huang, H. Zheng, X. Qin, Y. Yong, K. Cao, J. Huang and X. Lu, Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure, Acta Pharmacol. Sin. 32 (2011) 1345-1350; DOI: 10.1038/ aps.2011.96.
21. L.-Y. Chiu, J.-L. Ko, Y.-J. Lee, T.-Y. Yang, Y.-T. Tee and G.-T. Sheu, L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines, Toxicol. Lett. 192 (2010) 408-418; DOI: 10.1016/j. toxlet.2009.11.018.
22. O. A. Al-Shabanah, A. M. Osman, M. M. Al-Harbi, A. M. Al-Bekairi, N. M. Al-Gharably and S. A. Aziz, Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells, Chemotherapy 41 (1995) 368-377; DOI: 10.1159/000239369.
23. N. W. Revis and N. Marusi}, Effects of doxorubicin and its aglycone metabolite on calcium sequestration by rabbit heart, liver, and kidney mitochondria, Life Sci. 25 (1979) 1055-1063; DOI: 10.1016/0024-3205(79)90591-5.
24. E. Bachmann and G. Zbinden, Effect of doxorubicin and rubidazone on respiratory function and Ca2+ transport in rat heart mitochondria, Toxicol. Lett. 3 (1979) 29-34; DOI: 10.1016/0378-4274(79)90103-6.
25. X. Tan, D.-B. Wang, X. Lu, H. Wei, R. Zhu, S.-S. Zhu, H. Jiang and Z.-J. Yang, Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A, Biol. Pharm. Bull. 33 (2010) 1666-1672; DOI: 10.1248/bpb.33.1666.
26. A. V. Kuznetsov, R. Margreiter, A. Amberger, V. Saks and M. Grimm, Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death, Biochim. Biophys. Acta 1813 (2011) 1144-1152; DOI: 10.1016/j.bbamcr. 2011.03.002.
27. F. De Oliveira, C. Chauvin, X. Ronot, M. Mousseau, X. Leverve and E. Fontaine, Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells, Oncogene 25 (2006) 2646-2655; DOI: 10.1038/sj.onc.1209293.
28. S. E. Lipshultz, R. E. Scully, S. R. Lipsitz, S. E. Sallan, L. B. Silverman, T. L. Miller, E. V. Barry, B. L. Asselin, U. Athale, L. A. Clavell, E. Larsen, A. Moghrabi, Y. Samson, B. Michon, M. A. Schorin, H. J. Cohen, D. S. Neuberg, E. J. Orav and S. D. Colan, Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, Lancet Oncol. 11 (2010) 950-961; DOI: 10.1016/S1470-2045(10) 70204-7.
29. K. E. Merten, Y. Jiang, W. Feng and Y. J. Kang, Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway, J. Pharmacol. Exp. Ther. 319 (2006) 934-940; DOI: 10.1124/jpet. 106.108845.